Patients may prefer semaglutide injections like Ozempic or Wegovy over daily pills, especially with complex regimens or adherence challenges. Others favor the flexibility of oral forms like Rybelsus, including the option to occasionally skip doses to manage side effects.
FDA Approvals for Semaglutide
Ozempic (semaglutide) gained FDA approval in December 2017 for type 2 diabetes treatment. In 2023, the FDA approved an oral semaglutide formulation, Rybelsus, for the same indication.
The FDA mandates post-market surveillance for safety and efficacy. Check the FDA website for adverse events and recalls.
Patient Preferences: Injections vs Pills
The choice between injectable and oral semaglutide hinges on individual needs. Stanford Health Care highlights that injections suit those struggling with daily pills or managing multiple medications.
- Difficulty swallowing pills
- Gastrointestinal issues affecting absorption
- Preference for less frequent dosing—weekly injections simplify routines
For example, patients with diabetes, hypertension, and hyperlipidemia find weekly shots more convenient than added daily pills.
Travel and Lifestyle Considerations
Frequent travelers or those with irregular schedules may dislike daily pills due to missed doses or carrying challenges. The CDC offers guidance on traveling with medications, including documentation and storage.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Weekly injections appeal more for consistency across time zones. A business traveler crossing zones might adhere better to shots than timing daily pills.
Medication Adherence and Research Insights
Adherence—taking medication as prescribed—drives treatment success. NIH research links poor adherence to worse outcomes and higher costs.
Studies show oral medication adherence at 50-70%, often higher for less frequent injectables. Rates vary by patient, drug, and condition.
A 2021 Journal of the American Medical Association (JAMA) Network Open study found weekly semaglutide injections yielded significantly higher adherence than daily oral antidiabetics.
While consistent use is ideal, some providers note occasional missed oral doses may not greatly affect efficacy if mostly adherent. Apps like Shotlee help track GLP-1 doses for better compliance.
Individualized Treatment Plans
The American Diabetes Association (ADA) stresses tailored plans and shared decision-making. ADA standards recommend customizing treatments to patient preferences and needs.
